FT商学院

Trump’s drug price treatment is harsh but justified

The US is the biggest market for prescription drugs, accounting for roughly $600bn of annual sales out of a global $1tn or so

“You get what you pay for” has a nice ring to it. But it does not accurately describe the situation of those buying prescription pharmaceuticals in the US. President Trump, who has vowed to lower drugs prices by as much as 80 per cent, may finally have found a useful target for his sledgehammer. 

Drug prices have been a long-standing headache for successive US administrations. The complex system through which private insurers and state programmes buy pharmaceuticals means they pay a multiple of what comparable products cost in other countries.

您已阅读19%(548字),剩余81%(2394字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×